Desjardins Global Asset Management Inc. Alnylam Pharmaceuticals, Inc. Transaction History
Desjardins Global Asset Management Inc.
- $922 Million
- Q4 2023
A detailed history of Desjardins Global Asset Management Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Desjardins Global Asset Management Inc. holds 464 shares of ALNY stock, worth $124,347. This represents 0.01% of its overall portfolio holdings.
Number of Shares
464
Previous 458
1.31%
Holding current value
$124,347
Previous $81,000
8.64%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ALNY
# of Institutions
614Shares Held
108MCall Options Held
2.33MPut Options Held
2.17M-
Capital World Investors Los Angeles, CA15MShares$4.01 Billion0.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.5MShares$3.35 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.56 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA6.21MShares$1.66 Billion0.28% of portfolio
-
Baillie Gifford & CO6.03MShares$1.62 Billion1.16% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...